How Does the New Orexin Drug Treat Narcolepsy Type 1, a Sleep Disorder?

The FDA has approved Orzeyful, the first medicine to restore orexin signaling and treat the underlying cause of narcolepsy type 1.

Adults living with narcolepsy type 1 may soon have access to a treatment that does more than manage symptoms.
The US Food and Drug Administration (FDA) has approved Orzeyful (oveporexton), the first medicine designed to restore the missing orexin signaling responsible for the disorder, marking a major milestone in sleep medicine (1^✔ ✔Trusted Source
FDA Approves First Drug to Treat the Full Range of Narcolepsy Type 1 Symptoms

Go to source

).

The approval introduces a new approach to treating narcolepsy type 1. While currently available medicines mainly improve excessive daytime sleepiness or reduce sudden muscle weakness, Orzeyful targets the biological defect that causes the disease.

According to the FDA, it is the first treatment approved to address the full spectrum of narcolepsy type 1 symptoms by acting directly on the orexin system.

Why Is the FDA Approval of Orzeyful a Milestone for Narcolepsy Treatment?

According to the FDA, Orzeyful is the first medicine approved for adults with narcolepsy type 1 that treats the disorder as a whole rather than targeting individual symptoms. It is also the first therapy designed to restore orexin signaling, the biological pathway lost in people with this rare neurological condition.

Narcolepsy type 1 affects approximately 1 in 2,000 people in the United States.

The sleep disorder develops when the brain loses the neurons that produce orexin, a chemical messenger that helps regulate wakefulness, sleep, and muscle tone.

Without adequate orexin, the brain struggles to maintain a stable boundary between sleep and wakefulness, leading to a combination of disabling symptoms.

For years, treatment has relied on stimulants, wake-promoting medicines, antidepressants, or sodium oxybate to manage symptoms individually. According to the FDA, 1no previously approved medicine directly targeted the orexin pathway or treated narcolepsy type 1 as a unified disorder.

The agency also granted Orzeyful Breakthrough Therapy Designation and Priority Review, recognizing its potential to offer meaningful improvements over currently available treatments for a serious condition.

How Does Orzeyful Target the Root Cause of Narcolepsy Type 1?

Narcolepsy type 1 develops when the brain loses the neurons that produce orexin, a chemical messenger that regulates wakefulness, sleep, and muscle tone.

This loss disrupts the brain’s ability to maintain a stable sleep-wake cycle, leading to excessive daytime sleepiness, cataplexy, sleep paralysis, hallucinations, and disrupted nighttime sleep.

Orzeyful (oveporexton) is designed to restore the missing orexin signaling. Instead of masking symptoms, it targets the biological cause of narcolepsy type 1.

Researchers believe this represents a major change in treatment strategy. A Phase 2 trial published in the New England Journal of Medicine found that oveporexton significantly improved wakefulness, reduced excessive daytime sleepiness, and lowered cataplexy by restoring orexin receptor signaling (2^✔ ✔Trusted Source
Oveporexton, an Oral Orexin Receptor 2-Selective Agonist, in Narcolepsy Type 1

Go to source).

Patients also showed marked improvements in the Maintenance of Wakefulness Test (MWT) and Epworth Sleepiness Scale (ESS) after eight weeks of treatment.

Researchers writing in the Annals of Medicine and Surgery noted that current treatments mainly provide symptomatic relief and do not replace defective orexin signaling (3^✔ ✔Trusted Source
Orexin receptor 2 agonists: a pathophysiologic approach to narcolepsy type 1

Go to source).

They described orexin receptor agonists as a pathophysiology-based treatment approach that could shift narcolepsy care from symptom management toward targeting the underlying disease mechanism, although additional long-term studies are needed to confirm sustained benefits.

How Did Clinical Trials Support FDA Approval of Orzeyful?

The FDA approval of Orzeyful was backed by findings from both Phase 2 and Phase 3 clinical studies. The studies consistently showed improvements across multiple symptoms of narcolepsy type 1, suggesting that targeting orexin signaling may benefit the disorder as a whole rather than treating individual symptoms separately.

Key Findings from the Clinical Studies

Is Orzeyful Safe, and When Will It Become Available?

Orzeyful was generally well tolerated, and relatively few participants discontinued treatment because of side effects.

The most commonly reported side effects included:

• Insomnia
• Increased urinary frequency
• Urinary urgency
• Increased saliva production

The FDA advises that Orzeyful should not be taken together with strong CYP3A inhibitors, as these drugs may interfere with how the drug is metabolized. Its safety and effectiveness have also not been established in children and adolescents younger than 18 years (4^✔ ✔Trusted Source
FDA Approves ORZEYFUL â„¢, a First-in-Class Treatment for Adults With Narcolepsy Type 1

Go to source

).

Although the medicine has received FDA approval, it is not yet commercially available.

References:

1. FDA Approves First Drug to Treat the Full Range of Narcolepsy Type 1 Symptoms – (https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-full-range-narcolepsy-type-1-symptoms)
2. Oveporexton, an Oral Orexin Receptor 2–Selective Agonist, in Narcolepsy Type 1 – (https://www.nejm.org/doi/10.1056/NEJMoa2405847)
3. Orexin receptor 2 agonists: a pathophysiologic approach to narcolepsy type 1 – (https://pmc.ncbi.nlm.nih.gov/articles/PMC12768140/)
4. FDA Approves ORZEYFUL™, a First-in-Class Treatment for Adults With Narcolepsy Type 1 – (https://narcolepsynetwork.org/fda-approves-orzeyful-a-first-in-class-treatment-for-adults-with-narcolepsy-type-1/)

Source-Medindia